HDAC inhibitors and therapeutic methods using the same

US9249087B2 · kind B2 · utility

Assignees

• The Board of Trustees of the University of Illinois · US
• THE CHILDREN'S HOSPITAL OF PHILADELPHIA · US

Inventors

• Alan P. Kozikowski · Princeton, US
• Jay H. Kalin · Chicago, US
• Kyle Butler · Stanford, US
• Joel Bergman · Chicago, US
• Wayne W. Hancock · Philadelphia, US

Key dates

• Filing date: Jan 31, 2012
• Grant date: Feb 2, 2016
• Expiry date: Jan 31, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.